Sanofi, Regeneron skin cancer drug gets FDA nod
Sanofi Genzyme, the company’s speciality care unit and Regeneron will market Libtayo jointly in the United States.
Banglore: Sanofi SA has recently announced that its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.
The drug, Libtayo, is used to treat a rare form of skin cancer, in patients whose condition has not improved following surgery or chemotherapy.
Metastatic cutaneous squamous cell carcinoma is the second-most common form of skin cancer, which accounts for an estimated 7,000 deaths in the United States each year, Sanofi said.
Sanofi Genzyme, the company’s speciality care unit and Regeneron will market Libtayo jointly in the United States.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta)
Banglore: Sanofi SA has recently announced that its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.
The drug, Libtayo, is used to treat a rare form of skin cancer, in patients whose condition has not improved following surgery or chemotherapy.
Metastatic cutaneous squamous cell carcinoma is the second-most common form of skin cancer, which accounts for an estimated 7,000 deaths in the United States each year, Sanofi said.
Libtayo, which boosts the immune system to fight cancer, will be sold in the United States at a list price of $9,100 for a three-week treatment cycle.
Read Also: USFDA Approves Libtayo injection for treating metastatic cutaneous squamous cell carcinoma
Cancer immunotherapy has become the fastest-growing segment of the $100 billion-a-year cancer drug market, with sales expected to top $25 billion by 2021, according to analyst forecasts compiled by Thomson Reuters.
Sanofi Genzyme, the company’s speciality care unit and Regeneron will market Libtayo jointly in the United States.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd